(Q24236338)

title

Cardioprotective interventions for cancer patients receiving anthracyclines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457676&resulttype=core&format=json

13 May 2020

0 references

3

0 references

Elvira C. van Dalen

series ordinal

1

object named as

Elvira C van Dalen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457676&resulttype=core&format=json

13 May 2020

2

Huib N Caron

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457676&resulttype=core&format=json

13 May 2020

4

Leontien Cm Kremer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457676&resulttype=core&format=json

13 May 2020

author name string

Heather O Dickinson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457676&resulttype=core&format=json

Cochrane Database of Systematic Reviews

13 May 2020

publication date

15 June 2011

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457676&resulttype=core&format=json

13 May 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457676&resulttype=core&format=json

13 May 2020

page(s)

CD003917

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457676&resulttype=core&format=json

Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Cardiac toxicity of daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Doxorubicin cardiotoxicity: possible role of digoxin in its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Polyoxyethylene-modified superoxide dismutase reduces side effects of adriamycin and mitomycin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

A clinicopathologic analysis of adriamycin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

New anthracycline antitumor antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Combination therapy with probucol prevents adriamycin-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

A short multilingual quality of life questionnaire--practicability, reliability and interlingual homogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

Cardioprotective interventions for cancer patients receiving anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003917.PUB4

7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week

21 January 2018

1 reference

12 December 2020

Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients

1 reference

12 December 2020

Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation

1 reference

12 December 2020

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

1 reference

12 December 2020

Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane

1 reference

12 December 2020

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease

1 reference

12 December 2020

Should anthracyclines and dexrazoxane be used for children with cancer?

1 reference

12 December 2020

Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial

1 reference

12 December 2020

High-dose chemotherapy. Concepts and strategies

1 reference

12 December 2020

Verapamil in the prevention of adriamycin-induced cardiomyopathy

1 reference

12 December 2020

Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data

1 reference

12 December 2020

Cardiac and red blood cell glutathione peroxidase: results of a prospective randomized trial in patients on total parenteral nutrition

1 reference

12 December 2020

N-acetylcysteine prevents the doxorubicin-induced decrease of cyclic GMP

1 reference

12 December 2020

A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine

1 reference

12 December 2020

Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine

1 reference

12 December 2020

Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity

1 reference

12 December 2020

[Cardioprotection in chemo- and radiotherapy for malignant diseases--an echocardiographic pilot study]

1 reference

12 December 2020

Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial

1 reference

12 December 2020

[A questionnaire suitable for general practice for detection of the health status and quality of life of patients with hemato-oncologic diseases: psychometric properties. The Study G "Quality of Life" of the International Society for Chemo- and Immu

1 reference

12 December 2020

Anthracycline-induced cardiotoxicity

1 reference

12 December 2020

Cardioprotection in patients undergoing chemo- and/or radiotherapy for neoplastic disease. A pilot study

1 reference

12 December 2020

Early detection of the anthracycline-induced cardiotoxicity. A non-invasive haemodynamic study

1 reference

12 December 2020

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas

1 reference

12 December 2020

Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment

1 reference

12 December 2020

The role of iron in doxorubicin-induced cardiomyopathy.

1 reference

12 December 2020

10.1002/14651858.CD003917.PUB4

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

4184754

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457676&resulttype=core&format=json

13 May 2020

4184754

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6457676&resulttype=core&format=json

13 May 2020

PubMed publication ID

21678342

2 references

Consolidated OpenCitations Corpus – April 2017

4184754